Page 22 - Service Testing News Today

By Rob Curran Shares of oncology drug developer Kintara Therapeutics plunged after it suspended development of a brain-cancer treatment candidate, shifted...

By Ben Glickman Shares of Ocular Therapeutix rose Tuesday after a trial of its drug Dextenza met its primary endpoint. The stock was up 15% to $2.85 in...

By Ben Glickman Tonix Pharmaceuticals will discontinue development of its treatment for major depressive disorder after a study of the drug failed to meet...

By Dean Seal Deciphera Pharmaceuticals said the Phase 3 study of its treatment vimseltinib for tenosynovial giant cell tumors met its primary endpoint and...

By Chris Wack Reviva Pharmaceuticals Holdings said Monday that it saw positive topline results and successful completion of its pivotal Phase 3 trial...

Pfizer and BioNTech said an early trial of a combined Covid-19 and influenza vaccine had produced positive data. The companies are set for a race with...

By Robb M. Stewart BioXcel Therapeutics' shares rallied ahead of the opening bell Wednesday after the biopharmaceutical company said an independent audit of...

By Josh Beckerman BioVie said blinded data from a Phase 3 study of NE3107 suggest the drug is biologically active and may have impact on cognitive, biomarker...

Medical Device Testing Market by Service (Testing, Inspection, Certification), Sourcing (In-house, Outsourced), Technology (Active Implant, Active, Non-active, IVD, Ophthalmic, Orthopedic & Dental, Vascular), Class (I, II, III) – Global Forecast to 2028

By Sabela Ojea Boston Scientific said its clinical trial to treat coronary in-stent restenosis with its investigational device met its primary endpoint,...